The weekly litigation news digest is live. Subscribe now

Method Of Treating Proliferative Disorders And Other Pathological Conditions Mediated By Bcr-Abl, C-Kit, Ddr1, Ddr2 Or Pdgf-R Kinase Activity

Patent No. EP2501384 (titled "Method Of Treating Proliferative Disorders And Other Pathological Conditions Mediated By Bcr-Abl, C-Kit, Ddr1, Ddr2 Or Pdgf-R Kinase Activity") was filed by Novartis on Nov 17, 2010. The application was issued on Nov 1, 2023.

Patent Summary

UPC Cases New

Latest UPC cases involving this patent.

Case NumberFiling DatePlaintiffProceeding Type
UPC_CFI_382/2025Apr 29, 2025NovartisGeneric
APP_9038/2025Feb 28, 2025Zentiva KS, Zentiva PortugalGeneric
APP_10151/2025Feb 27, 2025Aliud PharmaGeneric
APP_68658/2024Dec 30, 2024StadapharmGeneric
UPC_CFI_698/2024Nov 14, 2024Accord Healthcare, Accord Healthcare SLUGeneric

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2501384

NOVARTIS
Application Number
EP10781781A
Filing Date
Nov 17, 2010
Status
Patent Maintained As Amended
Sep 29, 2023
Publication Date
Nov 1, 2023